DXS International PLC, a healthcare information and digital clinical decision support systems provider, reports a 5% revenue increase to £3,469,917 for the year ended 30 April 2025. The company faced a loss of £94,750 due to increased amortization and impairment costs, with R&D tax credits decreasing. SMART Referrals and Medicine Optimisation solutions show promising results, with new functionalities and revenue opportunities in secondary care. The NHS funding framework renewal in April 2026 is expected to drive revenue growth.

DXS International PLC continues to invest in innovative healthcare solutions with a focus on digital technology to address NHS challenges. The company’s Next-Gen SMART Referral system is undergoing user acceptance testing, with positive feedback expected to drive revenue growth in 2026/27. The ExpertCare Medicine Optimisation solution has shown a strong return on investment potential for the NHS in managing hypertension, with plans for further development and expansion across the NHS.

Financially, DXS International PLC reports a loss of £94,750 for the year ended 30 April 2025, with revenue increasing by 5% to £3,469,917. The company’s strategic focus on digital innovation and preventive care aligns with the NHS’s priorities, driving targeted funding towards technology-driven solutions. Despite challenges, DXS remains committed to delivering best-in-class solutions with a clear ROI for the NHS and shareholders.

The Directors of DXS International PLC have approved the financial statements for the year ended 30 April 2025, highlighting key accounting policies and estimates. The company’s going concern basis is supported by cash flow forecasts and anticipated revenue from new solutions. Impairment costs reflect investments in innovative products for the NHS, with optimism for future revenue growth. DXS continues to navigate challenges and seize opportunities in the evolving healthcare landscape.

Read more at GlobeNewswire: DXS International plc ((AQSE: DXSP)